305 related articles for article (PubMed ID: 15477758)
1. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.
Raut CP; Nawrocki S; Lashinger LM; Davis DW; Khanbolooki S; Xiong H; Ellis LM; McConkey DJ
Cancer Biol Ther; 2004 Dec; 3(12):1217-24. PubMed ID: 15477758
[TBL] [Abstract][Full Text] [Related]
2. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.
Ninomiya I; Nagai N; Oyama K; Hayashi H; Tajima H; Kitagawa H; Fushida S; Fujimura T; Ohta T
Oncol Rep; 2012 Sep; 28(3):777-84. PubMed ID: 22751903
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity.
Wei D; Wang L; He Y; Xiong HQ; Abbruzzese JL; Xie K
Cancer Res; 2004 Mar; 64(6):2030-8. PubMed ID: 15026340
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo.
Sawaoka H; Tsuji S; Tsujii M; Gunawan ES; Sasaki Y; Kawano S; Hori M
Lab Invest; 1999 Dec; 79(12):1469-77. PubMed ID: 10616198
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor and not cyclooxygenase 2 promotes endothelial cell viability in the pancreatic tumor microenvironment.
Toomey DP; Manahan E; McKeown C; Rogers A; McMillan H; Geary M; Conlon KC; Murphy JF
Pancreas; 2010 Jul; 39(5):595-603. PubMed ID: 20118820
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study.
Ferrandina G; Ranelletti FO; Legge F; Lauriola L; Salutari V; Gessi M; Testa AC; Werner U; Navarra P; Tringali G; Battaglia A; Scambia G
Clin Cancer Res; 2003 Oct; 9(12):4324-31. PubMed ID: 14555502
[TBL] [Abstract][Full Text] [Related]
8. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.
Leahy KM; Ornberg RL; Wang Y; Zweifel BS; Koki AT; Masferrer JL
Cancer Res; 2002 Feb; 62(3):625-31. PubMed ID: 11830509
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Gately S; Kerbel R
Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
[TBL] [Abstract][Full Text] [Related]
11. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer.
Connolly EM; Harmey JH; O'Grady T; Foley D; Roche-Nagle G; Kay E; Bouchier-Hayes DJ
Br J Cancer; 2002 Jul; 87(2):231-7. PubMed ID: 12107848
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
Fu SL; Wu YL; Zhang YP; Qiao MM; Chen Y
World J Gastroenterol; 2004 Jul; 10(13):1971-4. PubMed ID: 15222049
[TBL] [Abstract][Full Text] [Related]
13. [Inhibitory effects of cyclooxygenase-2 inhibitor celecoxib on growth and angiogenesis of human liver cancer HepG2 cell xenografts in small nude mice].
Zuo CH; Li ZR; Zhou X; Ouyang YZ; Zhou ZY; Zeng L
Ai Zheng; 2006 Apr; 25(4):414-20. PubMed ID: 16613672
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo.
Liu XH; Kirschenbaum A; Yao S; Lee R; Holland JF; Levine AC
J Urol; 2000 Sep; 164(3 Pt 1):820-5. PubMed ID: 10953162
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis.
Gallo O; Franchi A; Magnelli L; Sardi I; Vannacci A; Boddi V; Chiarugi V; Masini E
Neoplasia; 2001; 3(1):53-61. PubMed ID: 11326316
[TBL] [Abstract][Full Text] [Related]
17. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor.
Eibl G; Takata Y; Boros LG; Liu J; Okada Y; Reber HA; Hines OJ
Cancer Res; 2005 Feb; 65(3):982-90. PubMed ID: 15705899
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Majumder M; Xin X; Liu L; Girish GV; Lala PK
Cancer Sci; 2014 Sep; 105(9):1142-51. PubMed ID: 24981602
[TBL] [Abstract][Full Text] [Related]
19. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
20. Assessment of celecoxib pharmacodynamics in pancreatic cancer.
Jimeno A; Amador ML; Kulesza P; Wang X; Rubio-Viqueira B; Zhang X; Chan A; Wheelhouse J; Kuramochi H; Tanaka K; Danenberg K; Messersmith WA; Almuete V; Hruban RH; Maitra A; Yeo CJ; Hidalgo M
Mol Cancer Ther; 2006 Dec; 5(12):3240-7. PubMed ID: 17172427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
